Integra LifeSciences delivered a 30-minute presentation at the 44th Annual J.P. Morgan Healthcare Conference, emphasizing its neurosurgery and regenerative medicine franchises. Management highlighted the integration of its recent spinal fixation acquisition, projecting it will contribute $50 million in incremental revenue over the next 12 months. The company also outlined progress on its next-generation dural substitute, now entering a pivotal clinical trial with top-line readout expected in Q3 2025.

Seven brokerage firms covering Integra LifeSciences have issued ratings ranging from sell to buy, resulting in an average recommendation of “Reduce.” Three analysts recommend selling the shares, two recommend holding, and two recommend buying. The consensus 12-month price target stands at $15.00, with individual forecasts spanning from $11.00 to $17.00. Notably, JPMorgan raised its target from $12.00 to $13.00 while maintaining an underweight stance, and Wall Street Zen upgraded to a buy rating in November.

In its latest quarter, Integra reported non-GAAP earnings per share of $0.54, surpassing the consensus view by $0.11, and delivered revenue of $402.1 million, up 5.6% year-over-year but below the $414.3 million estimate. The firm recorded a negative net margin of 30.2% due to acquisition-related costs, while return on equity reached 14.1%. Management issued Q4 earnings guidance of $0.79 to $0.84 per share and full-year 2025 EPS guidance of $2.19 to $2.24, compared to the Street’s expectation of $2.45.

Director Jeffrey A. Graves increased his stake by purchasing 9,000 shares at an average of $11.35 per share, boosting his ownership by 28.1%. Insiders now hold 3.54% of shares outstanding. On the institutional front, Goldman Sachs added 35,790 shares in the first quarter, bringing its total to 1.66 million shares, while UBS Asset Management increased its position by 23%, acquiring 45,693 additional shares. Overall, institutional investors control 84.8% of the company’s stock.